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Increase in patients with central obesity and insulin resis-
tance is an important cause for the worldwide increased 
incidence of type 2 diabetes. Several risk factors such as 
glucose intolerance, hyperinsulinemia, obesity, dyslipid-
emia, and hypertension, but also endothelial dysfunction 
and inﬂammation, have been found to cluster and often 
precede type 2 diabetes mellitus. Seeing the importance 
of early identiﬁcation, the US National Cholesterol Edu-
cation Program created a readily applicable deﬁnition of 
the metabolic syndrome for daily clinical practice. It is 
assumed that the cardiovascular risk for patients belong-
ing to the metabolic syndrome can just be calculated 
out of the sum of the separate cardiovascular risk factors 
dyslipidemia and hypertension. However, there are also 
data pointing toward a higher risk than expected from 
these separate cardiovascular risk factors because of 
possible direct vascular effects of insulin resistance and 
obesity. Awareness of the underlying disorders of insulin 
resistance and its associated (non-) traditional risk fac-
tors such as endothelial dysfunction and inﬂammation 
is important for understanding the pathophysiology and 
thus coherent treatment.
Introduction 
The metabolic syndrome has received increasing atten-
tion over the past few years and is a subject of debate. The 
metabolic syndrome is conceptualized as a constellation of 
interrelated cardiovascular risk factors of metabolic origin 
that appear to directly promote the development of ath-
erosclerotic cardiovascular disease (CVD) and increase the 
risk for developing type 2 diabetes mellitus. The prevalence 
of type 2 diabetes has soared in the past decades because 
of changing lifestyle and eating habits; there are currently 
approximately 200 million people affected worldwide. 
Insulin resistance as a consequence of (abdominal) obesity 
(with approximately 400 million people affected world-
wide right now) is one of the main underlying causes of the 
increased incidence of type 2 diabetes.
The major long-term complications of type 2 diabetes 
are an increased risk of myocardial infarction, stroke, and 
peripheral vascular disease. Although microvascular com-
plications cause considerable morbidity in patients with 
type 2 diabetes, up to 80% of patients die from macrovas-
cular pathology [1]. Treatment of individual risk factors 
has been shown to reduce cardiovascular events in type 
2 diabetes. Dysglycemia does not appear to be the major 
determinant of CVD in type 2 diabetes, a concept sup-
ported by observations in the UKPDS (United Kingdom 
Prospective Diabetes Study) [2]. Individuals or patients 
with impaired glucose tolerance and/or impaired fast-
ing glucose are so-called prediabetic and are at risk for 
developing type 2 diabetes [3]. Treatment (with lifestyle 
recommendations and medication) as primary prevention 
of these individuals or patients can substantially reduce 
the risk of diabetes or death [4••]. Although in type 2 dia-
betes elevated plasma glucose concentrations may induce 
vascular damage, in prediabetic patients the increased 
cardiovascular risk is most likely the result of the patho-
physiologic phenomenon of insulin resistance, which leads 
to the occurrence of classic risk factors (eg, elevated blood 
pressure, low high-density lipoprotein [HDL] cholesterol, 
elevated triglycerides) and new risk factors such as inflam-
mation, hypercoagulability, hypoadiponectinemia, and 
impaired vasoreactivity [5].
The Operative Risk Factors in the Metabolic Syndrome Martens and Visseren 75
The Term “Metabolic Syndrome”
Many studies confirm that multiple cardiovascular risk 
factors of endogenous origin commonly aggregate in one 
individual. Several terms have been proposed to describe 
this clustering, but the term “metabolic syndrome” is 
most commonly used in the cardiovascular field. It is 
important to recognize that the metabolic syndrome is 
not a defined uniform entity. No clear pathogenesis has 
been elucidated and may not exist. The concept of the 
syndrome could range from a cluster of (un-) related risk 
factors to a constellation of risk factors linked through a 
common underlying mechanism.
Definitions of the Metabolic Syndrome
That the pathogenesis is not clear yet is shown in the dif-
ferent definitions several organizations have attempted 
to formulate in the effort to introduce the metabolic 
syndrome into clinical practice. All definitions include a 
measure of blood pressure, triglycerides, HDL cholesterol, 
and fasting glucose. They differ with respect to the selec-
tion of cutoff points and a measure of obesity.
NCEP
In contrast to the World Health Organization (WHO) and 
the European Group for Study of Insulin Resistance (EGIR) 
definitions, in which the presence of hyperinsulinemia as 
an indicator of insulin resistance is the starting point, the 
National Cholesterol Education Program (NCEP) definition 
is based on the number of abnormalities only, whereas the 
American Association of Clinical Endocrinologists (AACE) 
definition considers the number of abnormalities in selected 
subjects with high risk of insulin resistance. The latest 
International Diabetes Federation (IDF) definition considers 
abdominal obesity as the pathogenetic starting point.
WHO
In 1998, the WHO proposed the first definition, which 
emphasized that insulin resistance is the major underlying 
risk factor and required evidence of insulin resistance for 
diagnosis: impaired glucose tolerance, impaired fasting 
glucose, type 2 diabetes mellitus, or impaired disposal 
of glucose as measured by hyperinsulinemic-euglyce-
mic clamping. The other risk factors used for diagnosis 
included obesity, hypertension, high triglycerides, reduced 
HDL cholesterol level, or microalbuminuria [6].
EGIR
In 1999, the EGIR proposed a modification of the WHO 
definition by assuming that insulin resistance is the major 
cause and required evidence of hyperinsulinemia. Next 
to an elevated plasma insulin, microalbuminuria was 
replaced by an elevated plasma glucose to diagnose the 
insulin resistance syndrome. Patients with type 2 diabetes 
were excluded because insulin resistance was viewed pri-
marily as a risk factor for diabetes [7].
New definition by NCEP
For practical reasons, a new definition was introduced in 
2001 by the NCEP: the Adult Treatment Panel III (ATP 
III) criteria [8]. According to this definition, the metabolic 
syndrome can be diagnosed if at least three out of the fol-
lowing five (metabolic) abnormalities are present: elevated 
fasting glucose levels, elevated blood pressure, low plasma 
HDL cholesterol levels, elevated plasma triglycerides, and 
central obesity. Because the obligatory presence of insulin 
resistance is abandoned, this definition is easy to use for 
daily clinical practice.
AACE
In 2003, the AACE modified the ATP III criteria to refo-
cus on insulin resistance as the primary cause of metabolic 
risk factors [9]. Major criteria were impaired glucose tol-
erance, elevated triglycerides, reduced HDL cholesterol, 
elevated blood pressure, and obesity.
IDF
In 2005, a new definition for the metabolic syndrome was 
introduced by the IDF. Based on the obligatory presence 
of an increased waist circumference, it paid attention to 
the elementary role of abdominal obesity in the develop-
ment of the metabolic syndrome (Table 1) [10].
Prevalence of the Metabolic Syndrome and 
Risk for Cardiovascular Events
It is estimated that approximately one fifth of the US 
population has the metabolic syndrome, and prevalence 
increases with age. The prevalence of the metabolic 
syndrome in a healthy American population is approxi-
mately 24% [11]. In Europe, the prevalence seems similar, 
approximately 20%, with a difference between women 
(12%) and men (23%) [12,13]. In patients with clinical 
manifestations of vascular disease, the prevalence is 45%; 
and in patients with type 2 diabetes mellitus the preva-
lence is 80% [14]. Alternative definitions of the metabolic 
syndrome highly predict type 2 diabetes mellitus [15].
Table 1. Most used deﬁnition of the 
metabolic syndrome
Combination of 3 or more of the following parameters:
Fasting glucose ≥ 6.1 mmol/L and/or medication
Central obesity in terms of a waist > 102 cm for males 
and > 88 cm for females
Triglycerides ≥ 1.7 mmol/L; or speciﬁc treatment
HDL < 1.04 mmol/L for males and < 1.29 mmol/L for 
females; or speciﬁc treatment
Blood pressure ≥ 130/85 mm Hg and/or medication
HDL—high-density lipoprotein.
(From the National Cholesterol Education Program Adult 
Treatment Panel III [8].)
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Although different definitions have been used in vari-
ous studies, in most studies a similar increased risk of 
CVD of approximately twofold is found in patients with 
the metabolic syndrome compared to those without the 
metabolic syndrome [16–22,23•]. Associations between 
metabolic syndrome definitions and the risk of CVD 
ranged between 1.5 for fatal and nonfatal myocardial 
infarction or stroke for the NCEP definition in high-risk 
subjects with elevated cholesterol [20], and 3.7 for fatal 
and nonfatal coronary disease for the WHO definition 
in the general Italian population [24]. In addition, the 
metabolic syndrome is associated with advanced vascular 
damage in patients with coronary heart disease, stroke, 
peripheral arterial disease or abdominal aortic aneurysm 
[25], and untreated essential hypertension [26]. However, 
the ATP III but not the IDF criteria of the metabolic syn-
drome predict clinical cardiovascular events in subjects 
who underwent coronary angiography [27••].
The enormous number of people at risk for CVD and 
type 2 diabetes is about to increase dramatically because 
of the global increase in abdominal obesity [28].
Is It Dyslipidemia and High BP That Cause 
the Elevated Risk for Cardiovascular Events 
in the Metabolic Syndrome or Are There 
Direct Vascular Effects of Insulin Resistance 
and Obesity?
It is assumed that the cardiovascular risk for patients with 
the metabolic syndrome can be explained by the sum of 
the separate cardiovascular risk factors. However, there 
are also suggestions that the risk for developing CVD is 
more than just the sum of the separate cardiovascular 
risk factors [29•]. Moreover, the increased cardiovascu-
lar risk for patients with the metabolic syndrome cannot 
be completely explained by the traditional models for 
risk scoring, such as the Framingham score [20,30]. 
This increased cardiovascular risk may be due to the 
combination of nontraditional markers, which all have 
a relation with insulin resistance, together with the 
separate traditional components of the metabolic syn-
drome (hyperglycemia, hypertension, low plasma HDL 
cholesterol, high plasma triglyceride levels, and obesity). 
The nontraditional markers are endothelial dysfunc-
tion, inflammation, hyperinsulinemia, oxidative stress, 
hypercoagulability together with decreased fibrinolysis, 
decreased adiponectin levels, and increased small-dense 
low-density lipoprotein (LDL) [31–34].
Insulin Resistance and the Pathophysiology 
Behind the Clustered Risk Factors in 
Association with Central Obesity
Insulin is the most important regulator for the plasma glu-
cose level. It works by stimulating the disposal of glucose 
in skeletal muscle and adipose tissue and decreasing the 
hepatic glucose production. Furthermore, insulin stimu-
lates the lipogenesis and glycogen- and protein-synthase 
activity in adipocytes, liver, and skeletal muscle, and 
inhibits glycogenolysis, lipolysis, and protein breakdown 
(Fig. 1). In addition, insulin plays a role in the regulation 
of cell growth and differentiation.
Insulin resistance means that when insulin binds to the 
insulin receptor on the cell surface, this stimulation is not 
strong enough to induce the normal intracellular signal 
transduction with the consequence of insufficient reaction 
of target organs on insulin binding to the insulin receptor. 
In case of a sufficient pancreatic C-cell function, insulin 
resistance will lead to a compensatory hyperinsulinemia to 
maintain normoglycemia. Hyperglycemia follows by further 
increasing insulin resistance and after failure of the pancre-
atic C-cell function. Hyperinsulinemia has several important 
consequences as to cardiovascular risk, as described next.
Adipose tissue
Adipose tissue, especially intra-abdominal obesity, plays an 
important role in insulin resistance. In the INTERHEART 
study, abdominal obesity accounted for 44% of the risk of 
a first myocardial infarction [35••]. Adipose tissue is no 
longer only a depot, but can be seen as an endocrine organ 
[36]. Several products of adipose tissue may influence devel-
opment of insulin resistance. Important adipocyte-derived 
factors are free fatty acids (FFAs), tumor necrosis factor-B
(TNF-B), adiponectin, and leptin. High levels of FFAs have 
been linked to (the induction of) insulin resistance because 
increased FFA production in the liver leads to increased 
gluconeogenesis and decreased glucose metabolism in 
skeletal muscle [37]. Furthermore, high levels of FFAs will 
lead to an increase of very low density lipoprotein (VLDL), 
together with an increase of plasma triglycerides [38]. In 
an insulin-resistant state there is an attenuated lipoprotein 
lipase activity. Lipoprotein lipase is involved in the lipolysis 
of VLDL. Decreased breakdown of VLDL particles leads 
to reduced availability of small VLDL fragments and an 
increase in triglyceride-rich HDL particles via cholesterol 
ester transfer protein. Triglyceride-rich HDL particles are 
cleared faster by the liver, resulting in a decreased HDL 
plasma concentration and an increased triglyceride concen-
tration [39]. The expression of TNF-B by adipose tissue is 
upregulated in obesity and TNF-B levels are increased in 
patients with features of the insulin resistance syndrome (ie, 
endothelial dysfunction), inducing a higher risk of recurrent 
coronary events [40–42]. Adiponectin is an adipocyte-
derived hormone that decreases insulin resistance. A low 
adiponectin plasma concentration precedes a decrease in 
whole-body insulin sensitivity in humans [34,43,44]. The 
role of leptin in insulin resistance is controversial, but leptin 
might interfere with insulin signaling in certain cell types.
Hypertension
Hyperinsulinemia also causes hypertension. Normally 
insulin has a vasodilating effect; however, in an insulin-
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resistant state, insulin can cause sympathetic activation, 
production of the vasoconstrictor endothelin-1, and 
increase of renal salt retention. Together with, or leading 
to, endothelial dysfunction, leading to increased arterial 
resistance in the peripheral vasculature, these mecha-
nisms can result in elevated blood pressure [45]. Several 
studies showed a relation between hyperinsulinemia, 
increased plasma FFA levels, and more oxidized small-
dense LDL with endothelial dysfunction [46–48]. The 
Framingham study showed that abdominal obesity is the 
main hypertensinogenic factor [49]. A direct association 
between hypertension and body mass index has been 
observed in cross-sectional and longitudinal population 
studies from early childhood to old age [50]. The mecha-
nism by which obesity raises blood pressure is not fully 
understood, but increased body mass index is associated 
with an increase in plasma volume and cardiac output. 
These alterations and blood pressure can be decreased by 
weight loss in both normotensive and hypertensive sub-
jects. Furthermore, blood pressure in obese adolescents is 
sodium-sensitive, and fasting insulin is the best predictor 
of this sensitivity; after weight loss the blood pressure 
decreases and the salt sensitivity is reduced [51]. The 
variables that best predict sodium sensitivity are fasting 
plasma insulin, plasma aldosterone, and plasma norepi-
nephrine, supporting the hypothesis that blood pressure 
is sensitive to dietary sodium and that this sensitivity may 
be due to the combined effect of hyperinsulinemia, hyper-
aldosteronism, and increased activity of the sympathetic 
nervous system [52]. Hyperinsulinemia increases both 
sympathetic nerve activity and sodium and water reten-
tion. The expected vasodilation, upon binding of insulin 
to the endothelial insulin receptor and causing activation 
of endothelial nitric oxide synthase, is impaired in insu-
lin-resistant states [53]. It is also the heterogeneous effect 
of endogenous nitric oxide on proliferation along the vas-
cular tree that relates to the two different phenomenons 
of insulin-resistant vascular dysfunction. Endothelial 
dysfunction exists in conduit arteries, whereas elevated 
vascular resistance of resistance arteries is observed in 
essential hypertension [54,55].
Enhanced low-grade inflammation
Enhanced low-grade inflammation induces endothelial 
dysfunction by increased production of cytokines such as C-
reactive protein (CRP), TNF-B, and interleukin-6 [56–58]. 
In addition, increased high-sensitivity CRP is associated 
with obesity, insulin resistance, and endothelial dysfunc-
tion. The more components of the metabolic syndrome 
that are present in the same person, the higher the plasma 
CRP concentration [59]. It is noteworthy that CRP not only 
seems to function as an indicator for CVD, but CRP may 
also play a role as a risk factor in atherogenesis [60].
Discussion
The metabolic syndrome as an independent 
cardiovascular risk factor
Currently, a critical discussion is ongoing concerning the 
role of the metabolic syndrome in (cardiovascular) risk 
prediction [61]. The additive value of using the metabolic 
syndrome in the prediction of future cardiovascular risk 
compared with various alternative risk-score algorithms is 
not fully clear yet. From a clinical standpoint, presence of 
the metabolic syndrome identifies a person at increased 
















Figure 1. Pathophysiology of insulin 
resistance. FFA—free fatty acids; 
VLDL—very low density lipoprotein.
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understanding of the specific cause(s) of the syndrome 
may contribute to improved risk estimation for the devel-
opment of CVD and/or type 2 diabetes. For now, the 
presence of the syndrome is a more general indicator of 
higher risk for developing CVD and/or type 2 diabetes 
and may also give insight into the pathophysiology behind 
the occurrence of individual risk factors. This knowledge 
may lead to better treatment of risk factors.
The observation that cardiovascular risk factors tend 
to cluster in individual patients is intriguing and has trig-
gered basic and clinical researchers trying to understand 
and unravel the underlying pathophysiologic mechanisms 
behind this clustering. It is now generally accepted that 
insulin resistance plays an important and central role. The 
abdominal adipose tissue can be regarded as an organ with 
important endocrinologic functions, by the production of 
adipokines and cytokines, involved in energy homeosta-
sis, inflammation, and fibrinolysis. In case of adiposity, 
the production of several inflammatory cytokines such as 
TNF-B, leptin, and interleukin-6 is increased, whereas 
the production of adiponectin is diminished. This altera-
tion of adipokines is not only due to the excess of adipose 
tissue. Also, adipocyte dysfunction by itself contributes to 
the metabolic changes, which can be seen as a cause or a 
consequence of insulin resistance.
Treatment of the metabolic syndrome
Treatment of the metabolic syndrome has also been a topic 
of debate. It is assumed that the cardiovascular risk for 
patients with the metabolic syndrome can be calculated 
out of the sum of the separate cardiovascular risk factors. 
In the TNT (Treating to New Targets) study, univariate 
analysis of the individual characteristics of the metabolic 
syndrome showed a significant increased risk of major 
cardiovascular events with the presence of each compo-
nent of the metabolic syndrome. Furthermore, the risk of 
major cardiovascular events increased with the presence 
of each additional component of the metabolic syndrome. 
Interestingly, patients with coronary heart disease and the 
metabolic syndrome benefited from aggressive atorvastatin 
therapy, irrespective of the presence of diabetes [62••].
However, there are also data pointing toward a 
higher risk than could be expected from the separate 
cardiovascular risk factors (high triglycerides, low HDL, 
hyperglycemia, and high blood pressure) in relation to 
the metabolic syndrome. Treatment of these risk factors 
decreases the risk for cardiovascular events. Following 
this reasoning, reducing insulin resistance may further 
reduce the cardiovascular risk. New treatment strate-
gies and pharmacologic treatments need to be evaluated 
in this respect. In addition, insulin resistance leads to 
hypertension, hypertriglyceridemia, low HDL, small-
dense LDL, diminished fibrinolysis, and increased 
thrombogenicity. Because dysglycemia does not appear 
to be the major determinant of CVD in type 2 diabetes, 
targeting the underlying pathophysiologic mechanisms 
of the insulin resistance syndrome may be a more logical 
and beneficial strategy for reduction of cardiovascu-
lar morbidity and mortality. Although it is difficult to 
distinguish between the relative effects of insulin resis-
tance, it induces a significantly increased cardiovascular 
and cerebrovascular risk. This effect is consistent across 
the spectrum of worsening glycemic control, from the 
onset of impaired glucose tolerance to the development 
of clinical diabetes. From a pathophysiologic point of 
view, treatment should be focused on reducing insulin 
resistance, which can be achieved by weight reduction 
and an increase in physical activity. By decreasing 
insulin resistance, improvement of both the individual 
components of the metabolic syndrome (hyperglycemia, 
elevated blood pressure, decreased HDL cholesterol, 
elevated triglycerides, and central obesity) and the non-
classical associated risk factors (impaired fibrinolysis, 
oxidative stress, increased small dense LDL cholesterol, 
hypercoagulability, inflammation, hyperinsulinemia, 
and decreased adiponectin levels) could be expected. 
Reduction of insulin resistance not only reduces the 
risk for cardiovascular events, but could also prevent 
or delay the development of type 2 diabetes in patients 
at increased risk [63,64]. The very recently published 
DREAM (Diabetes Reduction Assessment with Ramipril 
and Rosiglitazone Medication) trial is the first study 
investigating the effects of lifestyle interventions and 
medication on clinical end points in patients diagnosed 
with the metabolic syndrome; it showed a reduction of 
the risk of diabetes or death by 60% in individuals at 
high risk for diabetes [4••]. This very promising result 
is stimulating for more studies with peroxisome pro-
liferator-activated receptor-H agonists, blockers of the 
endocannabinoid system, and therapeutic modulation 
of low adiponectin levels, all of which improve insulin 
sensitivity and influence the endocrine functions of the 
adipocyte, to investigate if treatment of patients with the 
metabolic syndrome without diabetes can be useful yet.
Although a pathophysiologic construct seems plau-
sible, future research must unravel pathophysiology and 
clinical use before the metabolic syndrome can be des-
ignated as a “syndrome” useful in daily clinical practice 
[65••]. The question of whether the cardiovascular risk 
associated with the metabolic syndrome is more than the 
sum of the risk caused by its parts is not answered and 
may never be answered. The only way to resolve this issue 
would be with a follow-up study investigating the hazards 
on cardiovascular morbidity and mortality for each indi-
vidual component, whereby during the follow-up period 
no other risk factors develop and no treatment occurs.
It is certain that the individual components (eg, dys-
lipidemia and hypertension) that make up the syndrome 
should be treated together. These are “the visible moun-
tains of the floating iceberg above the water.” However, 
there are other risk factors (ie, the direct vascular effects 
of insulin resistance and obesity) “underneath the water 
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surface” (Fig. 2). Awareness of the underlying disorders 
is important for understanding the pathophysiology and 
thus coherent treatment: be aware of insulin resistance 
and the associated (non-) traditional risk factors.
According to current guidelines for cardiovascular 
risk management, the presence of the metabolic syndrome 
may give direction to treatment [65••]. Identification of 
the metabolic syndrome not only has (therapeutic) conse-
quences for the individual patient but can also have major 
effects for public health care in terms of (future) costs 
and use of health care resources. Therefore, it is of great 
importance to have a diagnosis based on well-established 
diagnostic criteria that allows reliable estimation of risk.
Conclusions
Currently, a critical discussion is ongoing concerning 
the role of the metabolic syndrome in (cardiovascular) 
risk prediction. From a clinical standpoint, presence of 
the metabolic syndrome identifies a person at increased 
risk for CVD and/or type 2 diabetes. Eventually, a 
better understanding of the specific cause(s) of the syn-
drome may contribute to improved risk estimation for 
the development of CVD and/or type 2 diabetes and 
may lead to better treatment of risk factors. The indi-
vidual components (ie, dyslipidemia and hypertension) 
that make up the syndrome should be treated together. 
However, there are other risk factors, such as the 
direct vascular effects of insulin resistance and obesity. 
Awareness of the underlying disorders is important for 
understanding the pathophysiology and thus coherent 
treatment: be aware of insulin resistance and its associ-
ated (non-) traditional risk factors such as endothelial 
dysfunction and inflammation.
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